Predictive value of faecal calprotectin in ulcerative colitis – single centre experience

Abstract Objectives Faecal calprotectin is an important biomarker used in the evaluation of inflammatory bowel disease. The aim of this study was to establish the value of faecal calprotectin concentration as a predictor of remission in ulcerative colitis and its correlation with laboratory, endoscopic and clinical findings. Methods The single centre study included 126 adult patients with established diagnosis of ulcerative colitis consecutively visiting our Day clinic from March 2017 to March 2019. We measured serum biomarkers- CRP, haemoglobin, leukocytes and platelets. Faecal calprotectin was determined from stool, and endoscopy was performed with calculation of MAYO endoscopic subscore system (MES 0–1: remission, and MES 2–3: active disease). Clinical assessment was done by using Mayo score for ulcerative colitis (clinical Mayo score <2:remission, >5: active disease).The statistical analysis was performed using an univariate and multivariate model of disease remission prediction using logistic regression. Results According to univariate analysis the increase of faecal calprotectin concentration by 10 ug/g is associated with an 8% decrease in probability of disease remission (OR 0.9921, p < .05). In the multivariate analysis, faecal calprotectin remained a significant predictor of disease remission (OR 0.9948, 95% CI 0.9914–0.9982, p = .0028), however, with a significant contribution of C-reactive protein (OR 0.8340, 95% CI 0.7085–0.9818, p = .0292). According to our model the cut off value for faecal calprotectin was 154 ug/g. Conclusion Our results have shown that faecal calprotectin is an independent predictor of remission in UC patients. The results of our study represent real-life data from a single university centre dealing with FC as a prognostic marker in patients with UC. KEY MESSAGES Faecal calprotectin is an independent predictor of remission in UC patients. Recent studies have suggested that calprotectin correlates well with endoscopic activity of inflammation but correlation of faecal calprotectin in a phase of remission hasn’t been evaluated yet. We have found that other inflammatory biomarkers do not correlate well with either endoscopic or clinical activity in ulcerative colitis.

[1]  Carlisle Rainey,et al.  Estimating logit models with small samples , 2021, Political Science Research and Methods.

[2]  D. Schwartz,et al.  Assessing Severity of Disease in Patients with Ulcerative Colitis , 2020, Gastroenterology Clinics of North America.

[3]  M. Maniati,et al.  Calprotectin in inflammatory bowel disease , 2020, Clinica Chimica Acta.

[4]  G. Frieri,et al.  Is fecal calprotectin an accurate marker in the management of Crohn's disease? , 2019, Journal of gastroenterology and hepatology.

[5]  K. Goda,et al.  Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis , 2019, Scientific Reports.

[6]  P. Lakatos,et al.  Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? , 2019, World journal of gastroenterology.

[7]  G. D'Haens,et al.  Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review , 2019, Journal of Crohn's & colitis.

[8]  F. Costa,et al.  From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting , 2018, World journal of gastroenterology.

[9]  Takayuki Yamamoto,et al.  Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing , 2018, Clinical and Translational Gastroenterology.

[10]  Shan Gao,et al.  Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China , 2017, World journal of gastroenterology.

[11]  J. Gisbert,et al.  Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. , 2017, Digestive and Liver Disease.

[12]  I. Papaconstantinou,et al.  Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease , 2017, World journal of gastroenterology.

[13]  H. Puy,et al.  Fecal calprotectin in inflammatory bowel diseases: update and perspectives , 2017, Clinical chemistry and laboratory medicine.

[14]  A. Członkowska,et al.  Carotid intima media thickness and blood biomarkers of atherosclerosis in patients after stroke or myocardial infarction , 2016, Croatian medical journal.

[15]  H. Samant,et al.  Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease , 2015, Indian Journal of Gastroenterology.

[16]  W. Sandborn,et al.  C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis , 2015, The American Journal of Gastroenterology.

[17]  C. Beglinger,et al.  Fecal Calprotectin and the Clinical Activity Index Are Both Useful to Monitor Medical Treatment in Patients with Ulcerative Colitis , 2015, Digestive Diseases and Sciences.

[18]  K. Kolho,et al.  Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease , 2015, Scandinavian journal of gastroenterology.

[19]  M. Ciorba,et al.  Biomarkers in inflammatory bowel disease: current practices and recent advances. , 2012, Translational research : the journal of laboratory and clinical medicine.

[20]  J. Lewis.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. , 2011, Gastroenterology.

[21]  J. Mate,et al.  Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse , 2009, Inflammatory bowel diseases.

[22]  Q. Ouyang,et al.  Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. , 2008, World journal of gastroenterology.

[23]  B. Thjódleifsson,et al.  A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.

[24]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[25]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[26]  C. Fiocchi,et al.  Immunopathogenesis of IBD: current state of the art , 2016, Nature Reviews Gastroenterology &Hepatology.

[27]  S. Travis,et al.  Assessment of Disease Activity in Ulcerative Colitis , 2014 .

[28]  J. Jahnsen,et al.  Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. , 1997, Digestion.